Miller MD - Search Results

1

Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response.

Shulman NS, Zolopa AR, Passaro DJ, Murlidharan U, Israelski DM, Brosgart CL, Miller MD, Van Doren S, Shafer RW, Katzenstein DA. Shulman NS, et al. Among authors: miller md. J Acquir Immune Defic Syndr. 2000 Mar 1;23(3):221-6. doi: 10.1097/00126334-200003010-00002. J Acquir Immune Defic Syndr. 2000. PMID: 10839657

2

Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients.

Westland CE, Yang H, Delaney WE 4th, Wulfsohn M, Lama N, Gibbs CS, Miller MD, Fry J, Brosgart CL, Schiff ER, Xiong S. Westland CE, et al. Among authors: miller md. J Viral Hepat. 2005 Jan;12(1):67-73. doi: 10.1111/j.1365-2893.2005.00578.x. J Viral Hepat. 2005. PMID: 15655050

3

Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B.

Westland CE, Yang H, Delaney WE 4th, Gibbs CS, Miller MD, Wulfsohn M, Fry J, Brosgart CL, Xiong S; 437 and 438 Study Teams. Westland CE, et al. Among authors: miller md. Hepatology. 2003 Jul;38(1):96-103. doi: 10.1053/jhep.2003.50288. Hepatology. 2003. PMID: 12829991 Clinical Trial.

4

Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations.

Winters MA, Lloyd RM Jr, Shafer RW, Kozal MJ, Miller MD, Holodniy M. Winters MA, et al. Among authors: miller md. PLoS One. 2012;7(7):e40514. doi: 10.1371/journal.pone.0040514. Epub 2012 Jul 18. PLoS One. 2012. PMID: 22815755 Free PMC article.

5

Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1.

Westland C, Delaney W 4th, Yang H, Chen SS, Marcellin P, Hadziyannis S, Gish R, Fry J, Brosgart C, Gibbs C, Miller M, Xiong S. Westland C, et al. Gastroenterology. 2003 Jul;125(1):107-16. doi: 10.1016/s0016-5085(03)00700-5. Gastroenterology. 2003. PMID: 12851876 Clinical Trial.

6

Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovir + emtricitabine/lamivudine + efavirenz administered on a multiple tablet therapy.

Blanco JL, Montaner JS, Marconi VC, Santoro MM, Campos-Loza AE, Shafer RW, Miller MD, Paredes R, Harrigan R, Nguyen ML, Perno CF, Gonzalez-Hernandez LA, Gatell JM. Blanco JL, et al. Among authors: miller md. AIDS. 2014 Nov 13;28(17):2531-9. doi: 10.1097/QAD.0000000000000424. AIDS. 2014. PMID: 25574957

7

Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks.

Yang H, Westland CE, Delaney WE 4th, Heathcote EJ, Ho V, Fry J, Brosgart C, Gibbs CS, Miller MD, Xiong S. Yang H, et al. Among authors: miller md. Hepatology. 2002 Aug;36(2):464-73. doi: 10.1053/jhep.2002.34740. Hepatology. 2002. PMID: 12143057 Clinical Trial.

8

Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses.

Margot NA, Isaacson E, McGowan I, Cheng A, Miller MD. Margot NA, et al. Among authors: miller md. J Acquir Immune Defic Syndr. 2003 May 1;33(1):15-21. doi: 10.1097/00126334-200305010-00003. J Acquir Immune Defic Syndr. 2003. PMID: 12792350 Clinical Trial.

9

The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan.

DeGruttola V, Dix L, D'Aquila R, Holder D, Phillips A, Ait-Khaled M, Baxter J, Clevenbergh P, Hammer S, Harrigan R, Katzenstein D, Lanier R, Miller M, Para M, Yerly S, Zolopa A, Murray J, Patick A, Miller V, Castillo S, Pedneault L, Mellors J. DeGruttola V, et al. Antivir Ther. 2000 Mar;5(1):41-8. doi: 10.1177/135965350000500112. Antivir Ther. 2000. PMID: 10846592

10

Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408.

Miller MD, Margot NA, Lamy PD, Fuller MD, Anton KE, Mulato AS, Cherrington JM. Miller MD, et al. J Acquir Immune Defic Syndr. 2001 Aug 15;27(5):450-8. doi: 10.1097/00126334-200108150-00005. J Acquir Immune Defic Syndr. 2001. PMID: 11511821 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,111 results

Search Page